With 17.7% of residents at 65 or older [3], Medicare's $50 GLP-1 Bridge, for Part D enrollees who qualify, is the other main route [4].
Medical weight loss is care from a licensed prescriber who checks weight-related health and may prescribe an FDA-approved drug, such as semaglutide (Wegovy) or tirzepatide (Zepbound), alongside diet and activity changes.
At a glance
Bridge eligibility for Albuquerque Part D enrollees starts at a BMI of 35, or 30 or 27 with certain conditions, and each one-month fill costs $50 [4].
Bridge rules in plain termsTwelve months of Wegovy pens at $349 would take about 6.1% of Albuquerque's $68,317 median household income [2][3].
Under 65 and paying cashThe New Mexico Medical Board licenses the state's physicians; compounded semaglutide from any clinic or website is not FDA-approved [14][15].
License checks and compounded offers
A Medicare-heavy market
Albuquerque counted 556,588 residents in mid-2025, and 17.7% of them were 65 or older [3]. That share beats Chicago, Baltimore, St. Louis and Detroit [6] [7] [8] [9]. In Bernalillo County, 33.0% of adults had obesity in 2023 and 11.6% had a diabetes diagnosis [5]. For the older group, Medicare's new GLP-1 Bridge matters more than any cash deal.

Bridge rules in plain terms
- Window: a temporary CMS demonstration that runs July 1, 2026 to December 31, 2027, outside the regular Part D benefit [10].
- Your share: $50 for each one-month fill [4].
- Covered drugs: Wegovy pen and tablet, Foundayo and the Zepbound KwikPen. Ozempic and Zepbound vials do not qualify [10].
- BMI tests: age 18 or older on Part D, plus a BMI of at least 35; or at least 30 with heart failure with preserved ejection fraction, uncontrolled high blood pressure or kidney disease at stage 3a or beyond; or at least 27 with prediabetes or a past heart attack or stroke [4].
- Paperwork: Humana handles the prior authorization centrally and decides within 72 hours [10].
Read our Medicare GLP-1 guide and Wegovy and insurance for the rest.
Under 65 and paying cash
- Wegovy tablet$149 to $299 [2]
- Wegovy pen, starter fills$199 [2]
- Wegovy pen, regular$349 [2]
- Ozempic (diabetes)$349 to $499 [11]
Drug only. The starter price is for new patients and ends Dec 31, 2026.
| What | Cost per month | Notes |
|---|---|---|
| Wegovy pen, first two fills | $199 [2] | 0.25 and 0.5 mg only; new patients; ends Dec 31, 2026 |
| Wegovy pen, regular price | $349 [2] | Same price from 0.25 up to 2.4 mg |
| Wegovy tablet | $149 to $299 [2] | 1.5 mg $149, 4 mg $199, 9 or 25 mg $299 |
| Ozempic, for diabetes | $349, or $499 at 2 mg [11] | Not labeled for weight |
| Zepbound, vial or KwikPen | $299 to $449 [17] | $449 needs a refill within 45 days |
What moves an Albuquerque GLP-1 bill
- Pill or pen. Wegovy tablets cost $149 at 1.5 mg, $199 at 4 mg and $299 at 9 or 25 mg, while the pen is $349 at every strength [2].
- Molecule. Tirzepatide, sold for weight as Zepbound, runs $299 to $449 a month at LillyDirect by dose [17], and the Bridge takes its KwikPen but not its vials [10].
- Starter timing. A new patient's first two pen fills, at 0.25 and 0.5 mg, cost $199 each, but only through Dec 31, 2026 [2].
- The brand written. Ozempic, which has no weight label, runs $349, or $499 at 2 mg [11].
- Part D status. An Albuquerque Part D enrollee who meets the Bridge's BMI rules pays $50 for each one-month fill, through December 31, 2027 [4] [10].
- Clinic charges. The table counts medicine only, so a local prescriber's visit fees are added on top.
Albuquerque's median household income is $68,317 [3]. Twelve months of pens at $349 would take about 6.1% of it.
Choosing between the tablet and the pen
The tablet climbs from 1.5 mg to 4 mg and 9 mg, then reaches 25 mg after 90 days [12], with prices of $149, $199 and $299 along the way [2]. The pen reaches its maintenance dose at week 17 [12]. Ozempic, the diabetes brand, has no weight-loss approval [13]. See tablet vs injection.
License checks and compounded offers
The New Mexico Medical Board licenses the state's physicians [14]. When a clinic or website offers compounded semaglutide, know that FDA never approved it and does not review those products' safety, effectiveness or quality [15]. Learn more at compounded semaglutide, and look up online sellers in our FDA warning letter tracker.
Nearby in the Southwest: Phoenix, Scottsdale and Denver. Also see the weight loss hub, the semaglutide guide and the tirzepatide guide.
Safety for older adults
Vomiting or diarrhea can dry you out, and the label links that fluid loss to kidney injury. Gallbladder trouble and pancreatitis are listed risks; ongoing severe stomach pain needs a doctor. MTC or MEN 2 in you or a blood relative rules semaglutide out. Mention it to your surgical team before anesthesia [12]. For throat or face swelling or trouble breathing, call 911.
Questions people ask
What does semaglutide cost in Albuquerque without coverage?
As of Oct 17, 2026, NovoCare charged $349 a month for Wegovy pens, with $199 for a new patient's two starter fills through Dec 31, 2026, and $149 to $299 for Wegovy tablets [2].
What does Zepbound cost in Albuquerque without insurance?
LillyDirect listed Zepbound at $299 to $449 a month by dose on Oct 17, 2026, and the $449 price needs a refill within 45 days [17].
Does New Mexico Medicaid cover Wegovy?
Not for obesity. KFF's January 2026 review says New Mexico's program covers some weight-loss drugs but none of the GLP-1s for that use [1].
When does the Medicare GLP-1 Bridge run?
What BMI does the Bridge require?
At least 35; or 30 with certain heart, blood pressure or kidney conditions; or 27 with prediabetes or a prior heart attack or stroke. Enrollees must be 18 or older and on Part D [4].
How old is Albuquerque's population?
Older than most: Census QuickFacts puts 17.7% of the city's population at age 65 and up [3].
Who licenses physicians in Albuquerque?
The New Mexico Medical Board licenses physicians across the state [14].
What did the STEP 1 trial show?
The 2.4 mg group averaged a 14.9% drop in body weight at 68 weeks, while placebo averaged 2.4% [16].
Medical review: pending. A licensed clinician has not yet reviewed this page.
Sources
17 cited
- Medicaid Coverage of and Spending on GLP-1s. KFF, Jan 16, 2026.
- Wegovy self-pay offer. Novo Nordisk (NovoCare Pharmacy), accessed 2026-10-17.
- QuickFacts: Albuquerque city, New Mexico. U.S. Census Bureau, QuickFacts, V2025; ACS 2020-2024.
- Weight loss drugs coverage. Medicare.gov (CMS), accessed 2026-10-17.
- PLACES county data: Bernalillo County, NM. CDC PLACES (2025 release, BRFSS 2023), 2023 data, 2025 release.
- QuickFacts: Chicago city, Illinois. U.S. Census Bureau, QuickFacts, V2025; ACS 2020-2024.
- QuickFacts: Baltimore city, Maryland. U.S. Census Bureau, QuickFacts, V2025; ACS 2020-2024.
- QuickFacts: St. Louis city, Missouri. U.S. Census Bureau, QuickFacts, V2025; ACS 2020-2024.
- QuickFacts: Detroit city, Michigan. U.S. Census Bureau, QuickFacts, V2025; ACS 2020-2024.
- Medicare GLP-1 Bridge: information for pharmacies. Centers for Medicare & Medicaid Services, accessed 2026-10-17.
- Ozempic self-pay pricing. Novo Nordisk (NovoCare Pharmacy), accessed 2026-10-17.
- Wegovy label. DailyMed, NLM, Jun 2026.
- Ozempic label. DailyMed, NLM, May 2026.
- New Mexico Medical Board. State of New Mexico, accessed 2026-10-17.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. US Food and Drug Administration, Oct 1, 2026.
- Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine (PubMed), Feb 10, 2021.
- Zepbound self-pay pricing. Eli Lilly and Company (LillyDirect), Oct 17, 2026.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.